Dyno Therapeutics licenses AAV platform to Roche

By The Science Advisory Board staff writers

October 14, 2020 -- Dyno Therapeutics has licensed its CapsidMap platform for the development of next-generation adeno-associated virus (AAV) vectors for gene therapies for central nervous system (CNS) diseases and liver-directed therapies to Roche and its subsidiary Spark Therapeutics.

Dyno's proprietary platform identifies novel AAV capsids with optimized tissue targeting and immune-evading properties, in addition to improved packaging capacity and manufacturability, according to the company. CapsidMap uses artificial intelligence technology to design novel capsids and applies DNA library synthesis and next-generation DNA sequencing to measure in vivo gene delivery properties in high throughput.

Under the agreement, Dyno will be responsible for the design of novel AAV capsids with improved functional properties for gene therapy, and Roche and Spark will be responsible for conducting preclinical, clinical, and commercialization activities for gene therapy products using the novel capsids. Dyno will receive an undisclosed upfront payment and will be eligible for additional research payments as well as clinical and sales milestone payments and royalties for any resulting products. The potential milestone payments to Dyno may exceed $1.8 billion.

Regeneron, Roche increase supply of COVID-19 antibody cocktail
Regeneron Pharmaceuticals and Roche are joining forces to develop, manufacture, and distribute Regn-COV2, Regeneron's investigational antiviral antibody...
UCB, Roche to develop antibodies for Alzheimer's disease
Biopharmaceutical firm UCB has signed a deal to provide Roche and Genentech with an exclusive, worldwide license to its UCB0107 antitau antibody treatment...
Reverie Labs, Roche to advance kinase drug discovery
Reverie Labs is partnering with Roche and Genentech to advance next-generation kinase inhibitors with the use of artificial intelligence.
ThermoGenesis launches new cell processing products
ThermoGenesis has started distribution of the X-Series cell processing platform under the Corning Life Sciences brand, as part of an exclusive global...
Innovent, Roche partner on cell therapies, bispecific antibodies
Innovent Biologics has entered into a research and development collaboration with Roche for multiple cell therapies and bispecific antibodies.

Copyright © 2020 scienceboard.net

Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter